Acyltransferase

Acyltransferase Related Products (198):

By Effects:	Inhibitors (174) Activators (5) Substrate (1)

Cat. No.	Product Name	Effect	Purity

HY-119738

OSMI-1	Inhibitor	99.88%
OSMI-1 is a cell-permeable O-GlcNAc transferase (OGT) inhibitor with an IC₅₀ value of 2.7 μM. OSMI-1 inhibits protein O-linked N-acetylglucosamine (O-GlcNAcylation) in several mammalian cell lines without qualitatively altering cell surface N- or O-linked glycans.

HY-10038

A 922500	Inhibitor	99.33%
A 922500 (DGAT-1 Inhibitor 4a) is a potent, selective, and orally bioavailable diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC₅₀s of 9 and 22 nM against human and mouse DGAT-1, respectively.

HY-108341A

PF-06424439 methanesulfonate	Inhibitor	99.93%
PF-06424439 methanesulfonate is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ of 14 nM. PF-06424439 methanesulfonate is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.

HY-32219

T863	Inhibitor	99.83%
T863 is an orally active, selective and potent DGAT1 (acyl-CoA:diacylglycerol acyltransferase 1) inhibitor with an IC₅₀ of 15 nM. T863 has no inhibitory activity against human MGAT3, human DGAT2, or human MGAT2. T863 interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.

HY-108341

PF-06424439	Inhibitor	99.98%
PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC₅₀ of 14 nM. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.

HY-181943

SPT-IN-2	Inhibitor
SPT-IN-2 is an orally active serine palmitoyltransferase (SPT) inhibitor (with an IC₅₀ of 0.71 nM against human SPT2). SPT-IN-2 inhibits ceramide synthesis, suppresses cancer cell growth, and exhibits in vivo anti-tumor activity, favorable metabolic stability and cell membrane permeability in xenograft mouse models. SPT-IN-2 blocks the de novo sphingolipid synthesis pathway, significantly reducing intracellular ceramide levels and the levels of 3-ketodihydrosphingosine (3-KDS), the immediate downstream product of SPT. SPT-IN-2 can be used in research related to lung adenocarcinoma, acute promyelocytic leukemia and breast cancer.

HY-133491

ST1060	Inhibitor
ST1060, FTY720 (HY-12005) derivative, is a selective ceramide synthase 2 (CerS2) inhibitor. ST1060 can reduce the level of long-chain dihydroceramide (dhCer) catalyzed by CerS2 with IC₅₀ values of 63.6, and 61.3 μM for C_24:0 and C_24:1

HY-181719

NAT8L-IN-1	Inhibitor
NAT8L-IN-1 is a NAT8L inhibitor with an IC₅₀ value of 0.3 μM. NAT8L-IN-1 can be used for the research of Canavan disease.

HY-114361

OSMI-4	Inhibitor	99.69%
OSMI-4 is a low nanomolar O-GlcNAc transferase (OGT) inhibitor, with an EC₅₀ of 3 μM in cells.

HY-135425

10,12-Tricosadiynoic acid	Inhibitor	99.95%
10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism. 10,12-Tricosadiynoic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N6719

Fumonisin B1	Inhibitor	99.96%
Fumonisin B1 is a mycotoxin produced from Fusarium moniliforme. Fumonisin B1 is a potent inhibitor of sphingosine N-acyltransferase (ceramide synthase) and disrupts de novo sphingolipid biosynthesis. Fumonisin B1 is the most abundant and toxic fumonisin.

HY-13009

PF-04620110	Inhibitor	99.60%
PF-04620110 is a potent, selective and orally bioavailable diglyceride acyltransferase-1 (DGAT-1) inhibitor with an IC₅₀ of 19 nM.

HY-112489

FSG67	Inhibitor	99.95%
FSG67 is a glycerol 3-phosphate acyltransferase (GPAT) inhibitor with an IC₅₀ of 24 μM.

HY-W015239

KAT8-IN-1		99.61%
KAT8-IN-1 is a lysine (K) acetyltransferase 8 (KAT8) inhibitor, with IC₅₀s of 141 μM (KAT8), 221 μM (KAT2B), 106 μM (KAT3B), respectively. KAT8 inhibits histone acetyltransferases (HATs), and could result in disease states, such as cancer or inflammatory diseases.

HY-113054

DL-Glyceraldehyde 3-phosphate	Inhibitor
DL-Glyceraldehyde 3-phosphate is an intermediate in several metabolic pathways, including glycolysis and gluconeogenesis. DL-Glyceraldehyde 3-phosphate is a potent inhibitor of the growth of *E. coli. DL-Glyceraldehyde 3-phosphate is a competitive inhibitor of the acyltransferase*.

HY-P5282

ApoA-I mimetic peptide	Activator	98.90%
ApoA-I mimetic peptide is an ApoA-I mimetic peptide. ApoA-I mimetic peptide has good phosphatidylcholine: cholesterol acyltransferase (LCAT) activation activity. ApoA-I mimetic peptide can be used to synthesize peptide/lipid complexes. ApoA-I mimetic peptide can be used in atherosclerosis research. (The sequence is: PVLDLFRELLNELLEALKQKLK).

HY-117656

ESI-05	Inhibitor	99.78%
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders.

HY-16278

Pradigastat	Inhibitor	99.59%
Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC₅₀ at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC₅₀ of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.

HY-126015

P053	Inhibitor
P053 is a potent, non-competitive and selective ceramide synthase 1 (CerS1) inhibitor wirh an IC₅₀ of 0.5 μM. P053 acts as an endogenous inhibitor of mitochondrial fatty acid oxidation in muscle. Whole-body adiposity regulator.

HY-117832

Pyripyropene A	Inhibitor	99.37%
Pyripyropene A is an orally active, potent and selective sterol O-acyltransferase 2 (SOAT2)/acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) inhibitor, with an IC₅₀ of 0.07 µM. Pyripyropene A attenuates hypercholesterolemia and atherosclerosis in vivo.

Name
Email *

	Sorry, but the email address you supplied was invalid.